Saturday, May 11, 2013

Biotech investors are a stubborn and hopeful lot, and many of them will never give up the ship. While confidence and patience are admirable traits up to a point, it sometimes feels like some biotech investors would spin the sun going dark as a positive, as it means no more skin cancer. In the case of Dendreon (Nasdaq:DNDN), it's only the true believers and traders who have any confidence that this company has much of a future. With another very disappointing quarter in the books, I think the only real debate left to have is whether the company can survive.

Please click here to continue:
http://www.investopedia.com/stock-analysis/051013/little-left-dendreon-hope-trade-dndn-jnj-mdvn.aspx

0 comments:

Post a Comment